RedHill Biopharma is a specialty biopharmaceutical company that focuses on treating gastrointestinal and infectious diseases by promoting gastrointestinal drugs. The company's clinical late-stage investigational development programs include the development of drugs such as RHB-204 and opaganib to treat pulmonary nontuberculous mycobacteria infections and SARS-CoV-2 severe COVID-19 pneumonia, respectively. RedHill Biopharma was established in 2009 and is based in Tel Aviv, Israel.